Literature DB >> 24493722

Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative.

Marie E Wood1, Pamela Kadlubek, Trang H Pham, Dana S Wollins, Karen H Lu, Jeffrey N Weitzel, Michael N Neuss, Kevin S Hughes.   

Abstract

PURPOSE: Family history of cancer (CFH) is important for identifying individuals to receive genetic counseling/testing (GC/GT). Prior studies have demonstrated low rates of family history documentation and referral for GC/GT.
METHODS: CFH quality and GC/GT practices for patients with breast (BC) or colon cancer (CRC) were assessed in 271 practices participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative in fall 2011.
RESULTS: A total of 212 practices completed measures regarding CFH and GC/GT practices for 10,466 patients; 77.4% of all medical records reviewed documented presence or absence of CFH in first-degree relatives, and 61.5% of medical records documented presence or absence of CFH in second-degree relatives, with significantly higher documentation for patients with BC compared with CRC. Age at diagnosis was documented for all relatives with cancer in 30.7% of medical records (BC, 45.2%; CRC, 35.4%; P ≤ .001). Referall for GC/GT occurred in 22.1% of all patients with BC or CRC. Of patients with increased risk for hereditary cancer, 52.2% of patients with BC and 26.4% of those with CRC were referred for GC/GT. When genetic testing was performed, consent was documented 77.7% of the time, and discussion of results was documented 78.8% of the time.
CONCLUSION: We identified low rates of complete CFH documentation and low rates of referral for those with BC or CRC meeting guidelines for referral among US oncologists. Documentation and referral were greater for patients with BC compared with CRC. Education and support regarding the importance of accurate CFH and the benefits of proactive high-risk patient management are clearly needed.

Entities:  

Mesh:

Year:  2014        PMID: 24493722      PMCID: PMC4876350          DOI: 10.1200/JCO.2013.51.4661

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

Review 1.  Reconsidering the family history in primary care.

Authors:  Eugene C Rich; Wylie Burke; Caryl J Heaton; Susanne Haga; Linda Pinsky; M Priscilla Short; Louise Acheson
Journal:  J Gen Intern Med       Date:  2004-03       Impact factor: 5.128

Review 2.  Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2005-09-06       Impact factor: 25.391

3.  A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative.

Authors:  Michael N Neuss; Christopher E Desch; Kristen K McNiff; Peter D Eisenberg; Dean H Gesme; Joseph O Jacobson; Mohammad Jahanzeb; Jennifer J Padberg; John M Rainey; Jeff J Guo; Joseph V Simone
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

4.  Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.

Authors:  Katrina F Trivers; Laura-Mae Baldwin; Jacqueline W Miller; Barbara Matthews; C Holly A Andrilla; Denise M Lishner; Barbara A Goff
Journal:  Cancer       Date:  2011-07-25       Impact factor: 6.860

5.  Primary care physician management, referral, and relations with specialists concerning patients at risk for cancer due to family history.

Authors:  M E Wood; B S Flynn; A Stockdale
Journal:  Public Health Genomics       Date:  2013-01-17       Impact factor: 2.000

6.  Value of database linkage: are patients at risk of familial colorectal cancer being referred for genetic counselling and testing?

Authors:  C Wong; P Gibbs; J Johns; I Jones; I Faragher; E Lynch; F Macrae; L Lipton
Journal:  Intern Med J       Date:  2007-10-03       Impact factor: 2.048

7.  Genetic services for hereditary breast/ovarian and colorectal cancers - physicians' awareness, use and satisfaction.

Authors:  J C Carroll; M Cappelli; F Miller; B J Wilson; E Grunfeld; C Peeters; A G W Hunter; C Gilpin; P Prakash
Journal:  Community Genet       Date:  2008-01-15

8.  Screening for prostate cancer in high risk populations.

Authors:  William J Catalona; Jo Ann V Antenor; Kimberly A Roehl; Judd W Moul
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

9.  Family history-taking in community family practice: implications for genetic screening.

Authors:  L S Acheson; G L Wiesner; S J Zyzanski; M A Goodwin; K C Stange
Journal:  Genet Med       Date:  2000 May-Jun       Impact factor: 8.822

10.  Most patients with colorectal tumors at young age do not visit a cancer genetics clinic.

Authors:  Lucia I H Overbeek; Nicoline Hoogerbrugge; Joannes H J M van Krieken; Fokko M Nagengast; Theo J M Ruers; Marjolijn J L Ligtenberg; Rosella P M G Hermens
Journal:  Dis Colon Rectum       Date:  2008-08       Impact factor: 4.585

View more
  69 in total

1.  Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.

Authors:  Terri Febbraro; Katina Robison; Jennifer Scalia Wilbur; Jessica Laprise; Amy Bregar; Vrishali Lopes; Robert Legare; Ashley Stuckey
Journal:  Gynecol Oncol       Date:  2015-04-28       Impact factor: 5.482

2.  Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.

Authors:  Anita Y Kinney; Rachel Howell; Rachel Ruckman; Jean A McDougall; Tawny W Boyce; Belinda Vicuña; Ji-Hyun Lee; Dolores D Guest; Randi Rycroft; Patricia A Valverde; Kristina M Gallegos; Angela Meisner; Charles L Wiggins; Antoinette Stroup; Lisa E Paddock; Scott T Walters
Journal:  Contemp Clin Trials       Date:  2018-09-18       Impact factor: 2.226

3.  Electronically ascertained extended pedigrees in breast cancer genetic counseling.

Authors:  V Stefansdottir; H Skirton; O Th Johannsson; H Olafsdottir; G H Olafsdottir; L Tryggvadottir; J J Jonsson
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

Review 4.  What characterizes cancer family history collection tools? A critical literature review.

Authors:  J E Cleophat; H Nabi; S Pelletier; K Bouchard; M Dorval
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

Review 5.  Hereditary Polyposis Syndromes.

Authors:  Trilokesh D Kidambi; Divyanshoo R Kohli; N Jewel Samadder; Aparajita Singh
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

6.  A randomized controlled intervention to promote readiness to genetic counseling for breast cancer survivors.

Authors:  Monica L Kasting; Claire C Conley; Aasha I Hoogland; Courtney L Scherr; Jongphil Kim; Ram Thapa; Maija Reblin; Cathy D Meade; M Catherine Lee; Tuya Pal; Gwendolyn P Quinn; Susan T Vadaparampil
Journal:  Psychooncology       Date:  2019-04-11       Impact factor: 3.894

Review 7.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

8.  Evolution of Hereditary Breast Cancer Genetic Services: Are Changes Reflected in the Knowledge and Clinical Practices of Florida Providers?

Authors:  Deborah Cragun; Courtney Scherr; Lucia Camperlengo; Susan T Vadaparampil; Tuya Pal
Journal:  Genet Test Mol Biomarkers       Date:  2016-08-15

9.  Compatibility of Family History Cancer Guidelines With Meaningful Use Standards.

Authors:  Ayesha Aziz; Lance Pflieger; Nathaniel O'Connell; Joshua Schiffman; Brandon M Welch
Journal:  JCO Clin Cancer Inform       Date:  2017-11-07

10.  A high frequency of BRCA mutations in young black women with breast cancer residing in Florida.

Authors:  Tuya Pal; Devon Bonner; Deborah Cragun; Alvaro N A Monteiro; Catherine Phelan; Lily Servais; Jongphil Kim; Steven A Narod; Mohammad R Akbari; Susan T Vadaparampil
Journal:  Cancer       Date:  2015-08-19       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.